Commentary
Video
Dr Mauz-Koerholz on the Role of Pembrolizumab in Younger Patients With Low-Risk Classic Hodgkin Lymphoma
Author(s):
Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.
Christine Mauz-Koerholz, MD, PhD, Department of Pediatric Hematology and Oncology, Martin Luther University Halle-Wittenberg, discusses updated results from the phase 2 KEYNOTE-667 trial (NCT03407144) of pembrolizumab (Keytruda) in children, adolescents, and young adults with low-risk classic hodgkin lymphoma and slow early response to front line chemotherapy. These findings were presented at the 2024 ASH Annual Meeting by Mauz-Koerholz and colleagues.
Related Videos
Related Content
